Characterization of Angiotensin II Molecular Determinants Involved in AT1 Receptor Functional Selectivity
- 1 June 2015
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 87 (6) , 982-995
Abstract
The octapeptide angiotensin II (AngII) exerts a variety of cardiovascular effects through the activation of the AngII type 1 receptor (AT1), a G protein-coupled receptor. The AT1 receptor engages and activates several signalling pathways, including heterotrimeric G proteins Gq and G12, as well as the ERK1/2 pathway. Additionally, following stimulation, β-arrestin is recruited to the AT1 receptor, leading to receptor desensitization. It is increasingly recognized that specific ligands selectively bind and favour the activation of some signalling pathways over others, a concept termed ligand bias or functional selectivity. A better understanding of the molecular basis of functional selectivity may lead to the development of better therapeutics with fewer adverse effects. In the present study, we developed assays allowing the measurement of 6 different signalling modalities of the AT1 receptor. Using a series of AngII peptide analogs that were modified in positions 1, 4 and 8, we sought to better characterize the molecular determinants of AngII that underlie functional selectivity of the AT1 receptor in HEK293 cells. The results reveal that position 1 of AngII does not confer functional selectivity, while position 4 confers a bias towards ERK signalling over Gq signalling and that position 8 confers a bias towards β-arrestin recruitment over ERK activation and Gq signalling. Interestingly, the analogs modified in position 8 were also partial agonists of the PKC-dependent ERK pathway via atypical PKC isoforms PKCζ and PKCι.Keywords
This publication has 35 references indexed in Scilit:
- Differential β-Arrestin–Dependent Conformational Signaling and Cellular Responses Revealed by Angiotensin AnalogsScience Signaling, 2012
- A Simple Method for Quantifying Functional Selectivity and Agonist BiasACS Chemical Neuroscience, 2012
- Selectively Engaging β-Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac PerformanceThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Ligand‐directed signalling at β‐adrenoceptorsBritish Journal of Pharmacology, 2010
- Regulation of RhoGEF proteins by G12/13‐coupled receptorsBritish Journal of Pharmacology, 2009
- Independent β-Arrestin2 and Gq/Protein Kinase Cζ Pathways for ERK Stimulated by Angiotensin Type 1A Receptors in Vascular Smooth Muscle Cells Converge on Transactivation of the Epidermal Growth Factor ReceptorJournal of Biological Chemistry, 2009
- Endothelial Nitric Oxide Synthase Inhibits G12/13and Rho-Kinase Activated by the Angiotensin II Type-1 ReceptorArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Pressor response induced by central angiotensin II is mediated by activation of Rho/Rho-kinase pathway via AT1 receptorsJournal Of Hypertension, 2007
- Protein Kinase C-ζ Mediates Angiotensin II Activation of ERK1/2 in Vascular Smooth Muscle CellsJournal of Biological Chemistry, 1997
- Agonist-receptor efficacy II: agonist trafficking of receptor signalsTrends in Pharmacological Sciences, 1995